FY2025 · ended Dec 31, 2025 · Revenue $350,000 · Filed Feb 19, 2026
Pulse Biosciences, Inc. (PLSE) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $350,000 and a net loss of $72.8 million. Free cash flow was -$54.4 million. As of Sep 30, 2026 it held $36.7 million in cash and investments and $6.4 million in total debt.
Revenue (TTM)
$1.49M
+1637.2% vs year-ago TTM
Net income (TTM)
$-83.72M
-12.0% vs year-ago TTM
Operating cash flow (TTM)
$-63.33M
-30.6% vs year-ago TTM
Free cash flow (TTM)
$-63.70M
-30.6% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
68.23M
+0.3% vs prior year
Net cash
$30.36M
as of Sep 30, 2026
Operating margin
-5821.1%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PLSE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1625101
- Former names
- Electroblate, Inc. (until Nov 13, 2014)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $350,000 | $0 | $0 | $700,000 | $1.4M |
| Operating income | -$76.9M | -$56.3M | -$43.6M | -$58.1M | -$63.0M |
| Net income | -$72.8M | -$53.6M | -$42.2M | -$58.5M | -$63.7M |
| Operating cash flow | -$54.1M | -$36.3M | -$33.0M | -$47.0M | -$54.1M |
| Free cash flow | -$54.4M | -$36.5M | -$33.2M | -$47.4M | -$54.5M |
| Total assets | $94.5M | $132.5M | $59.2M | $77.9M | $54.2M |
| Total liabilities | $13.9M | $17.6M | $14.8M | $80.1M | $18.6M |
| Stockholders' equity | $80.7M | $114.9M | $44.4M | -$2.2M | $35.7M |
| Cash and investments | $80.7M | $118.0M | $44.4M | $61.1M | $28.6M |
| Total debt | $7.5M | $8.9M | $9.1M | $10.0M | $10.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Sep 15, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
All 641 Pulse Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.